LICENSE AGREEMENTS (Details) € in Thousands					1 Months Ended			3 Months Ended					12 Months Ended
	Jul. 20, 2022 USD ($)	Aug. 05, 2021 USD ($)	Nov. 30, 2020 USD ($)	Jul. 30, 2020 USD ($)	Jul. 31, 2022 USD ($)	Aug. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Mar. 31, 2021 EUR (€)	Dec. 31, 2020 USD ($)	Dec. 31, 2020 EUR (€)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)
Organization And Basis Of Presentation [Line Items]
Asset purchase agreement, variable consideration								$ 30,000,000					$ 30,000,000
Payments to refund license agreement deposits	$ 3,000,000
Qilu Pharmaceutical Co., Ltd. | Licensing Agreements
Organization And Basis Of Presentation [Line Items]
Upfront payment				$ 12,000,000
Total milestone payments				$ 23,000,000
Royalty payment, percentage				12.00%
University of Zurich
Organization And Basis Of Presentation [Line Items]
Royalty payment obligation, percent													4.00%	4.00%
Third party maximum ownership, percent													10.00%	10.00%
Third party minimum ownership, percent													2.00%	2.00%
Expenses related to achievement of development milestone						$ 500,000	$ 300,000
University of Zurich | Collaborative Arrangement, Revenue Based on Clinical Development Milestone
Organization And Basis Of Presentation [Line Items]
License agreement, amount payable upon achievement of specified milestone													$ 500,000
Micromet AG
Organization And Basis Of Presentation [Line Items]
Royalty payment obligation, percent													3.50%	3.50%
Expenses related to achievement of development milestone									$ 600,000	€ 500	$ 900,000	€ 700	$ 51,770	€ 50
Potential milestone payments													$ 2,600,000	€ 2,400
License agreement, royalty payment, reduction, conditions not met													1.50%	1.50%
License maintenance fees | €														€ 50
XOMA Ireland Limited
Organization And Basis Of Presentation [Line Items]
License agreement, amount payable upon achievement of specified milestone													$ 250,000
Royalty payment obligation, percent													2.50%	2.50%
Third party maximum ownership, percent													50.00%	50.00%
Third party minimum ownership, percent													1.75%	1.75%
Roche
Organization And Basis Of Presentation [Line Items]
Other receivable, asset purchase agreement								30,000,000					$ 30,000,000
Proceeds from execution of asset purchase agreement					$ 40,000,000
Roche | EBI-031
Organization And Basis Of Presentation [Line Items]
Other receivable, asset purchase agreement					$ 70,000,000
Qilu Pharmaceutical Co., Ltd.
Organization And Basis Of Presentation [Line Items]
License agreement, amount payable upon achievement of specified milestone													$ 200,000
Royalty period				12 years
License termination fee						$ 1,400,000
License termination payment								$ 1,200,000
MENA License Agreement | Licensing Agreements
Organization And Basis Of Presentation [Line Items]
Upfront payment			$ 3,000,000
Eczacibasi Pharmaceuticals Marketing Agreement
Organization And Basis Of Presentation [Line Items]
Potential milestone payments		$ 2,000,000
Transaction price		$ 1,500,000
Eczacibasi Pharmaceuticals Marketing Agreement | TURKEY
Organization And Basis Of Presentation [Line Items]
Royalty revenue, percentage		0.30